+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Psoriatic Arthritis - Market Insight, Epidemiology and Market Forecast - 2030

  • ID: 5387738
  • Report
  • July 2021
  • Region: Global
  • 270 pages
  • DelveInsight

FEATURED COMPANIES

  • AbbVie
  • AltruBio
  • Bristol-Myers Squibb
  • Janssen Biotech
  • Janssen Biotech
  • Pfizer
This ‘Psoriatic Arthritis (PsA)- Market Insights, Epidemiology, and Market Forecast - 2030' report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Psoriatic Arthritis in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Psoriatic Arthritis market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Psoriatic Arthritis Market Size from 2018 to 2030, segmented by 7MM major markets. The report also covers the current Psoriatic Arthritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2018-2030

Psoriatic Arthritis: Disease Understanding and Treatment Algorithm

Psoriatic Arthritis Overview

Psoriatic arthritis (PsA) is a form of arthritis associated with psoriasis, chronic skin, and nail disease characterized by red, scaly rashes, and thick pitted fingernails. The disease is similar to rheumatoid arthritis in symptoms, characterized by joint inflammation. However, psoriatic arthritis tends to affect fewer joints than rheumatoid arthritis and does not produce the typical rheumatoid arthritis antibodies.

Arthritis associated with psoriasis was first described in 1956 by Wright. However, it was not until 1973 that Moll and Wright defined the various clinical phenotypes, including axial PsA, symmetrical polyarthritis, asymmetrical oligoarthritis, distal interphalangeal (DIP) arthritis, and arthritis mutilans. The following year, these authors introduced the concept of spondyloarthritis, a cluster of diseases with shared clinical and immunogenetic features. Despite these advances, the immunopathogenesis of PsA remained poorly understood, awaiting a more detailed understanding of immune networks and the inflammatory response.

The etiology and pathogenesis of PsA involve a complex interaction between genetic and environmental factors resulting in immune-mediated inflammation involving the skin and joints and may involve other organs. Approximately 33-50% of psoriatic arthritis patients have at least one first-degree relative who also has psoriasis or PsA. Genes associated with PsA include those in the HLA region, which are involved in antigen presentation and immune recognition along withnon-HLA genes involved in immune activation and inflammation including intracellular signaling, cytokine expression, and signaling, and T-cell effector function. The role of environmental factors is suspected but has been difficult to confirm. Skin trauma is known to induce flares of psoriatic skin lesions known as the Koebner phenomenon. There is evidence the joint trauma may induce a flare of arthritis, referred to as the “internal” or “deep” Koebner phenomenon.

PsA shares some clinical features with other inflammatory arthritides, including rheumatoid arthritis (RA), reactive arthritis (ReA), and ankylosing spondylitis (AS). In some cases, it is difficult to make a precise diagnose. Unlike PsA, RA tends to be symmetrical and generally spares the DIP joints. AS has an earlier age of onset compared to psoriatic arthritis, and sacroiliac involvement is usually symmetric rather than asymmetric.

There are no laboratory tests that are specific for PsA. Acute phase reactants such as ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein) may become elevated as in most inflammatory diseases. However, a normal ESR and CRP should not be used to rule out a diagnosis of PsA as these levels increase in only about 40% of patients. Besides, imaging plays a central role. Classical radiography has been used for this purpose for over a hundred years. It allows identifying the late stages of the disease when bone tissue is affected. In the last 20 years, many new imaging modalities, such as ultrasonography (US), computed tomography (CT), and magnetic resonance (MR), have been developed and became important diagnostic tools for the evaluation of rheumatoid diseases. They enable the assessment and monitoring of early inflammatory changes. As a result, patients have earlier access to modern treatment, and thus the formation of destructive changes in joints can be markedly delayed or even avoided.

PsA may range from mild to severe, and it is crucial to treat it no matter the severity. If left untreated, PsA can cause permanent joint damage, which may be disabling. In addition to preventing irreversible joint damage, treating PsA may also help reduce inflammation in the body, leading to other diseases. These other diseases are often referred to as comorbidities. However, at present, no cure for PsA exists, so treatment goals are to slow disease progression, improve quality of life, lessen pain, and preserve the range of motion. In most patients with PsA, pharmacological treatment consists of a trial-and-error approach, beginning with corticosteroids and nonsteroidal anti-inflammatory drugs to manage symptoms. Physicians often use conventional synthetic disease-modifying antirheumatic drugs (DMARDs), followed by biological DMARDs if a patient does not adequately respond.

Psoriatic Arthritis Diagnosis and Treatment

It covers conventional and current medical therapies and diagnosis available in the Psoriatic Arthritis market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The Psoriatic Arthritis market report thoroughly understands Psoriatic Arthritis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for Psoriatic Arthritis in the US, Europe, and Japan.

Psoriatic Arthritis Epidemiology

The Psoriatic Arthritis epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Psoriatic Arthritis epidemiology segmented as the Prevalent Cases of Psoriatic Arthritis, diagnosed cases of Psoriatic Arthritis, Age-specific Cases of Psoriatic Arthritis, Gender-specific cases of Psoriatic Arthritis, and Severity-specific Prevalence of Psoriatic Arthritis. The report includes the prevalent scenario of Psoriatic Arthritis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Psoriatic Arthritis Epidemiology

The epidemiology segment also provides the Psoriatic Arthritis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total diagnosed prevalence population of Psoriatic Arthritis in the 7MM was estimated to be 1,486,869 cases in 2020.

Psoriatic Arthritis Drug Chapters

The drug chapter segment of the Psoriatic Arthritis report encloses the detailed analysis of Psoriatic Arthritis marketed drugs and late stage (Phase-III, Phase-II and Phase-I/II) pipeline drugs. It also helps to understand the Psoriatic Arthritis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

PsA treatments are not one-size-fits-all; the current treatment strategy in PsA emphasizes a target to target approach to the prevalent domains. Advances in the knowledge of pathogenesis have led to the development of novel biologics beyond anti-TNFs. However, there is still a substantial proportion of patients who may not respond to certain treatment options. The current practice relies on individualizing treatment choice by matching the most severely affected domains of the patients with the best available evidence of efficacies of drugs for those domains. When patients do not respond to treatment, shifting and cycling through different options would be rational.

Psoriatic Arthritis Emerging Drugs

Skyrizi (AbbVie) is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is linked to several chronic immune-mediated diseases, including psoriasis. Skyrizi received US Food and Drug Administration (FDA) approval to treat moderate-to-severe plaque psoriasis (Ps) in adults who are candidates for systemic therapy or phototherapy. The drug is approved in Japan for treating plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis, and PsA in adults who have an inadequate response to conventional therapies. Phase III trials of Skyrizi in psoriasis, Crohn's disease, and PsA are ongoing. With positive top-line results from two important phases III trials for psoriatic arthritis, the company filed regulatory submissions for PsA in FDA and EMA and expects FDA approval for treating psoriatic arthritis in 2022.

Ilumya (tildrakizumab-asmn) (Sun Pharma) is an interleukin-23 (IL-23) inhibitor, already indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, in the United States, Australia, and Japan and under the brand name ILUMETRI in Europe. The drug is currently under phase III evaluation and is expected to enter the market by 2023.

Psoriatic Arthritis Market Outlook

The Psoriatic Arthritis market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Psoriatic Arthritis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Psoriatic Arthritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to clearly view the market at first sight.

According to the publisher, the Psoriatic Arthritis market in the 7MM is expected to change in the study period 2018-2030.

Rising awareness about the disease, evolving patient research prospective, supporting government policies, funds, approvals, and emerging research would significantly drive the market in the forecast period (2021-2030).

AbbVie holds the highest market position among all the current pharma players despite facing tough competition and the emergence of biosimilars due to its strategic launch of two candidate drugs Rinvoq and Skyrizi, in the upcoming years. Both the drugs are already approved in the US and EU market: Rinvoq to treat moderately to severely active rheumatoid arthritis and risankizumab to treat moderate to severe plaque psoriasis. Also, Rinvoq got the latest approval in the EU market for PsA, and Skyrizi is already approved in Japan. Hence, with the subsequent launch of these drugs, Abbvie is likely to continue to dominate the therapeutic market.

Key Findings

This section includes a glimpse of the Psoriatic Arthritis market in the 7MM. The market size of Psoriatic Arthritis in the 7MM was USD 6420 Million in 2020.

The United States: Market Outlook

This section provides the total Psoriatic Arthritis market size and market size by therapies of Psoriatic Arthritis in the United States.

The United States accounts for the highest market size of Psoriatic Arthritis compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Ever since the Food and Drug Administration (FDA) granted Enbrel (etanercept) marketing authorization for the treatment of PsA in 2002, the market has become increasingly competitive as more biologics for PsA come to market. Also, with the emergence of numerous treatment options, the treatment guidelines have been further updated to reflect the improved efficacy and safety of these newer medications on the market.

The American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF) recently issued evidence-based guidelines for the pharmacologic and nonpharmacologic treatment of active psoriatic arthritis. The number of disease-modifying antirheumatic drugs (DMARDs) indicated for PsA has increased during the last decade. The armamentarium now includes not only conventional synthetic DMARDs (csDMARDs) such as methotrexate (MTX), sulfasalazine and leflunomide, and tumor necrosis factor inhibitors (TNFi), but also other targeted biological agents aimed at different cytokines, such as TNF, interleukin (IL)-12/23 and IL-17A, as well as targeted synthetic DMARDs (tsDMARDs) that inhibit phosphodiesterase-4 (PDE4) or Janus kinases (JAKs).

EU-5 Countries: Market Outlook

The total Psoriatic Arthritis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.

Japan Market Outlook

The total Psoriatic Arthritis market size and market size by therapies of Psoriatic Arthritis in Japan are also mentioned.

Psoriatic Arthritis Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018-2030. The analysis covers Psoriatic Arthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Psoriatic Arthritis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase I/II stage. It also analyses Psoriatic Arthritis key players involved in developing targeted therapeutics.

Major players include UCB Biopharma, AbbVie, Bristol-Myers Squibb, Sun Pharma, and others, whose key products are expected to launch in the US market by 20XX.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Psoriatic Arthritis emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working in the Psoriatic Arthritis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Psoriatic Arthritis market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs a Competitive and Market Intelligence analysis of the Psoriatic Arthritis market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of Psoriatic Arthritis, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the Psoriatic Arthritis epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Psoriatic Arthritis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Psoriatic Arthritis market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Psoriatic Arthritis market.
Report Highlights
  • In the coming years, the Psoriatic Arthritis market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world, expanding the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Psoriatic Arthritis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Psoriatic Arthritis. The launch of emerging therapies will significantly impact the Psoriatic Arthritis market
  • A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for Psoriatic Arthritis.
  • The in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Psoriatic Arthritis Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Psoriatic Arthritis Pipeline Analysis
  • Psoriatic Arthritis Market Size and Trends
  • Market Opportunities
  • Impact of Upcoming Therapies
Psoriatic Arthritis Report Key Strengths
  • 10-years Forecast
  • 7MM Coverage
  • Psoriatic Arthritis Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake
Psoriatic Arthritis Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions Answered

Market Insights:
  • What were the Psoriatic Arthritis Market share (%) distribution in 2018, and how would it look like in 2030?
  • What would be the Psoriatic Arthritis total market Size and market Size by therapies across the 7MM during the forecast period (2018-2030)?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest Psoriatic Arthritis market Size during the forecast period (2018-2030)?
  • At what CAGR, the Psoriatic Arthritis market is expected to grow in the 7MM during the forecast period (2018-2030)?
  • What would be the Psoriatic Arthritis market outlook across the 7MM during the forecast period (2018-2030)?
  • What would be the Psoriatic Arthritis market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
  • What are the disease risk, burden, and unmet needs of Psoriatic Arthritis?
  • What is the historical Psoriatic Arthritis patient pool in 7MM major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Psoriatic Arthritis in 7MM major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Psoriatic Arthritis?
  • Out of all 7MM countries, which country would have the highest prevalent population of Psoriatic Arthritis during the forecast period (2018-2030)?
  • At what CAGR the population is expected to grow in the 7MM during the forecast period (2018-2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
  • What are the current options for the treatment of Psoriatic Arthritis?
  • What are the current treatment guidelines for treating Psoriatic Arthritis in the US, Europe, and Japan?
  • What are the Psoriatic Arthritis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Psoriatic Arthritis?
  • How many therapies are developed by each company for the treatment of Psoriatic Arthritis?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Psoriatic Arthritis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Psoriatic Arthritis therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Psoriatic Arthritis and their status?
  • What are the key designations that have been granted for the emerging therapies for Psoriatic Arthritis?
  • What are the global historical and forecasted market for Psoriatic Arthritis?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving the Psoriatic Arthritis market.
  • To understand the future market competition in the Psoriatic Arthritis market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Psoriatic Arthritis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Psoriatic Arthritis market.
  • To understand the future market competition in the Psoriatic Arthritis market.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie
  • AltruBio
  • Bristol-Myers Squibb
  • Janssen Biotech
  • Janssen Biotech
  • Pfizer
1. Key Insights

2. Report Introduction

3. Psoriatic Arthritis Market Overview at a Glance
3.1. Market Share (%) Distribution of Psoriatic Arthritis in 2018
3.2. Market Share (%) Distribution of Psoriatic Arthritis in 2030

4. Executive Summary of Psoriatic Arthritis

5. Disease Background and Overview
5.1. Introduction
5.2. Clinical Manifestations
5.3. Classification
5.4. Risk Factors
5.5. Pathogenesis of PSA
5.6. Diagnosis
5.7. Differential Diagnosis
5.8. Treatment and Management
5.8.1. ACR/NPF Recommendations for Psoriatic arthritis
5.8.2. Summary of differences in recommendations
5.8.3. EULAR Recommendations

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. 7MM Total Prevalent Population of Psoriatic arthritis (PsA)
6.3. Epidemiology of Psoriatic arthritis (PsA)
6.4. The United States
6.4.1. Prevalent Cases of Psoriatic arthritis (PsA) in the United States
6.4.2. Diagnosed Cases of Psoriatic arthritis (PsA) in the US
6.4.3. Age-specific Cases of Psoriatic Arthritis in the United States
6.4.4. Gender-specific cases of Psoriatic Arthritis in the United States
6.4.5. Severity-specific Prevalence of Psoriatic Arthritis in the United States
6.5. EU5
6.5.1. Germany
6.5.1.1. Prevalent Cases of Psoriatic arthritis (PsA) in Germany
6.5.1.2. Diagnosed Cases of Psoriatic arthritis (PsA) in Germany
6.5.1.3. Age-specific Cases of Psoriatic Arthritis in Germany
6.5.1.4. Gender-specific cases of Psoriatic Arthritis in Germany
6.5.1.5. Severity-specific Prevalence of Psoriatic Arthritis in Germany
6.5.2. France
6.5.2.1. Prevalent Cases of Psoriatic arthritis (PsA) in France
6.5.2.2. Diagnosed Cases of Psoriatic arthritis (PsA) in France
6.5.2.3. Age-specific Cases of Psoriatic Arthritis in France
6.5.2.4. Gender-specific cases of Psoriatic Arthritis in France
6.5.2.5. Severity-specific Prevalence of Psoriatic Arthritis in France
6.5.3. Italy
6.5.3.1. Prevalent Cases of Psoriatic arthritis (PsA) in Italy
6.5.3.2. Diagnosed Cases of Psoriatic arthritis (PsA) in Italy
6.5.3.3. Age-specific Cases of Psoriatic Arthritis in Italy
6.5.3.4. Gender-specific cases of Psoriatic Arthritis in Italy
6.5.3.5. Severity-specific Prevalence of Psoriatic Arthritis in Italy
6.5.4. Spain
6.5.4.1. Prevalent Cases of Psoriatic arthritis (PsA) in Spain
6.5.4.2. Diagnosed Cases of Psoriatic arthritis (PsA) in Spain
6.5.4.3. Age-specific Cases of Psoriatic Arthritis in Spain
6.5.4.4. Gender-specific cases of Psoriatic Arthritis in Spain
6.5.4.5. Severity-specific Prevalence of Psoriatic Arthritis in Spain
6.5.5. The United Kingdom
6.5.5.1. Prevalent Cases of Psoriatic arthritis (PsA) in the United Kingdom
6.5.5.2. Diagnosed Cases of Psoriatic arthritis (PsA) in the United Kingdom
6.5.5.3. Age-specific Cases of Psoriatic Arthritis in the United Kingdom
6.5.5.4. Gender-specific cases of Psoriatic Arthritis in the United Kingdom
6.5.5.5. Severity-specific Prevalence of Psoriatic Arthritis in the United Kingdom
6.5.6. Japan
6.5.6.1. Prevalent Cases of Psoriatic arthritis (PsA) in Japan
6.5.6.2. Diagnosed Cases of Psoriatic arthritis (PsA) in Japan
6.5.6.3. Age-specific Cases of Psoriatic Arthritis in Japan
6.5.6.4. Gender-specific cases of Psoriatic Arthritis in Japan
6.5.6.5. Severity-specific Prevalence of Psoriatic Arthritis in Japan

7. Organizations contributing towards Psoriatic arthritis (PsA)

8. Patient Journey

9. Case Reports

10. Marketed Products
10.1. Key cross Competition
10.2. Humira (Adalimumab): AbbVie
10.2.1. Product Description
10.2.2. Regulatory Milestones
10.2.3. Safety and Efficacy of Humira
10.2.4. Side effects of Humira
10.2.5. Product Profile
10.3. Enbrel (Etanercept): Amgen/Pfizer
10.3.1. Product Description
10.3.2. Regulatory Milestones
10.3.3. Safety and Efficacy of Enbrel
10.3.4. Side effects of Enbrel
10.3.5. Product Profile
10.4. Orencia (Abatacept): Bristol-Myers Squibb
10.4.1. Product Description
10.4.2. Regulatory Milestones
10.4.3. Safety and Efficacy of Orencia
10.4.4. Side effects of Orencia
10.4.5. Product Profile
10.5. Simponi (Golimumab): Janssen Biotech
10.5.1. Product Description
10.5.2. Regulatory Milestones
10.5.3. Safety and Efficacy of Simponi
10.5.4. Side effects of Simponi
10.5.5. Product Profile
10.6. Remicade (Infliximab): Janssen Biotech
10.6.1. Product Description
10.6.2. Regulatory Milestones
10.6.3. Other development activities
10.6.4. Safety and Efficacy of Remicade
10.6.5. Side effects of Remicade
10.6.6. Product Profile
10.7. Otezla (Apremilast): Amgen
10.7.1. Product Description
10.7.2. Regulatory Milestones
10.7.3. Safety and Efficacy of Otezla
10.7.4. Side effects of Otezla
10.7.5. Product Profile
10.8. Stelara (ustekinumab): Janssen Biotech
10.8.1. Product Description
10.8.2. Regulatory Milestones
10.8.3. Safety and Efficacy of Stelara
10.8.4. Side effects of Stelara
10.8.5. Product Profile
10.9. Taltz (ixekizumab): Eli Lilly and Company
10.9.1. Product Description
10.9.2. Regulatory Milestones
10.9.3. Safety and Efficacy of Taltz
10.9.4. Side effects of Taltz
10.9.5. Product Profile
10.10. Cosentyx (Secukinumab): Novartis
10.10.1. Product Description
10.10.2. Regulatory Milestones
10.10.3. Other development activities
10.10.4. Safety and Efficacy of Cosentyx
10.10.5. Side effects of Cosentyx
10.10.6. Product Profile
10.11. Tremfya (Guselkumab): Janssen Biotech
10.11.1. Product Description
10.11.2. Regulatory Milestones
10.11.3. Other development activities
10.11.4. Safety and Efficacy of Tremfya
10.11.5. Side effects of Tremfya
10.11.6. Product Profile
10.12. Xeljanz (Tofacitinib): Pfizer
10.12.1. Product Description
10.12.2. Regulatory Milestones
10.12.3. Safety and Efficacy of Tremfya
10.12.4. Side effects of Tremfya
10.12.5. Product Profile
10.13. Cimzia (Certolizumab pegol): UCB
10.13.1. Product Description
10.13.2. Regulatory Milestones
10.13.3. Other development activities
10.13.4. Safety and Efficacy of Cimzia
10.13.5. Side effects of Cimzia
10.13.6. Product Profile

11. Emerging Therapies
11.1. Key Cross Competition
11.2. Skyrizi (risankizumab): AbbVie
11.2.1. Drug Description
11.2.2. Regulatory Milestones
11.2.3. Other development activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.2.7. Product Profile
11.3. Rinvoq (Upadacitinib): AbbVie
11.3.1. Drug Description
11.3.2. Regulatory Milestones
11.3.3. Clinical Development
11.3.4. Clinical Trials Information
11.3.5. Safety and Efficacy
11.3.6. Product Profile
11.4. Deucravacitinib: Bristol-Myers Squibb
11.4.1. Drug Description
11.4.2. Clinical Development
11.4.3. Clinical Trials Information
11.4.4. Safety and Efficacy
11.4.5. Product Profile
11.5. Tildrakizumab: Sun Pharma Global FZE
11.5.1. Drug Description
11.5.2. Other Development Activities
11.5.3. Clinical Development
11.5.4. Clinical trial information
11.5.5. Safety and Efficacy
11.5.6. Product Profile
11.6. Bimekizumab: UCB Biopharma
11.6.1. Drug Description
11.6.2. Other Development Activities
11.6.3. Clinical Development
11.6.4. Clinical trial information
11.6.5. Safety and Efficacy
11.6.6. Product Profile
11.7. Neihulizumab: AltruBio
11.7.1. Drug Description
11.7.2. Clinical Development
11.7.3. Clinical Trial Information
11.7.4. Safety and Efficacy
11.7.5. Product Profile
11.8. Brepocitinib (PF 6700841): Pfizer
11.8.1. Drug Description
11.8.2. Clinical Development
11.8.3. Clinical Trials Information
11.8.4. Safety and Efficacy
11.8.5. Product Profile

12. Psoriatic arthritis (PsA): Seven Major Market Analysis
12.1. Key Findings
12.2. Market Size of Psoriatic arthritis (PsA) in 7MM
12.3. Market Outlook
12.4. United States Market Size
12.4.1. Total Market Size of Psoriatic arthritis (PsA)
12.4.2. Market Size of Psoriatic arthritis (PsA) by Systemic Therapies (Class-wise)
12.4.3. Market Size of Psoriatic arthritis (PsA) by Product
12.5. EU-5 Market
12.5.1. Germany
12.5.1.1. Total Market Size of Psoriatic arthritis (PsA) in Germany
12.5.1.2. Market Size of Psoriatic arthritis (PsA) by Systemic Therapies (Class-wise) in Germany
12.5.1.3. Market Size of Psoriatic arthritis (PsA) by Product in Germany
12.5.2. France
12.5.2.1. Total Market Size of Psoriatic arthritis (PsA) in France
12.5.2.2. Market Size of Psoriatic arthritis (PsA) by Systemic Therapies (Class-wise) in France
12.5.2.3. Market Size of Psoriatic arthritis (PsA) by Product in France
12.5.3. Italy
12.5.3.1. Total Market Size of Psoriatic arthritis (PsA) in Italy
12.5.3.2. Market Size of Psoriatic arthritis (PsA) by Systemic Therapies (Class-wise) in Italy
12.5.3.3. Market Size of Psoriatic arthritis (PsA) by Product in Italy
12.6. Spain
12.6.1.1. Total Market Size of Psoriatic arthritis (PsA) in Spain
12.6.1.2. Market Size of Psoriatic arthritis (PsA) by Systemic Therapies (Class-wise) in Spain
12.6.1.3. Market Size of Psoriatic arthritis (PsA) by Product in Spain
12.7. United Kingdom
12.7.1.1. Total Market Size of Psoriatic arthritis (PsA) in United Kingdom
12.7.1.2. Market Size of Psoriatic arthritis (PsA) by Systemic Therapies (Class-wise) in United Kingdom
12.7.1.3. Market Size of Psoriatic arthritis (PsA) by Product in United Kingdom
12.8. Japan Market Size
12.8.1.1. Total Market Size of Psoriatic arthritis (PsA) in Japan
12.8.1.2. Market Size of Psoriatic arthritis (PsA) by Systemic Therapies (Class-wise) in Japan
12.8.1.3. Market Size of Psoriatic arthritis (PsA) by Product in Japan

13. KOL Views

14. Unmet Needs

15. Market Drivers

16. Market Barriers

17. SWOT Analysis

18. Market Access

19. Appendix
19.1. Bibliography

20. Report Methodology

21. Publisher Capabilities

22. Disclaimer

23. About the Publisher

List of Tables
Table 1: Summary of Psoriatic Arthritis, Epidemiology, and Key Events (2018-2030)
Table 2: CASPAR criteria
Table 3: Moll and Wright Classification
Table 4: Operational definition of classification of psoriatic arthritis
Table 5: Suggested Diagnostic Algorithm
Table 6: Clinical characteristics of different types of arthritis that can aid differential diagnosis
Table 7: 2018 ACR/NPF Recommendations for the initial treatment for active psoriatic arthritis who are OSM‐ and other treatment naive
Table 8: 2018 ACR/NPF Recommendations for active PsA despite treatment with a TNFi biologics
Table 9: 2018 ACR/NPF Recommendations for active PsA despite treatment with an IL‐17i or an IL‐12/23i biologics
Table 10: 2018 ACR/NPF Recommendations for PsA including treat‐to‐target, active axial disease, enthesitis, or active inflammatory bowel disease
Table 11: 2018 ACR/NPF Recommendations for PsA and comorbidities, including concomitant diabetes and recurrent-serious infections
Table 12: 2018 ACR/NPF Recommendations for nonpharmacologic interventions in patients with active PsA regardless of pharmacologic treatment status
Table 13: Summary of differences in recommendations
Table 14: 2019 EULAR recommendations for the pharmacological management of psoriatic arthritis
Table 15: Prevalent Population of Psoriatic arthritis in 7MM (2018-2030)
Table 16: Prevalent Cases of Psoriatic arthritis (PsA) in the United States (2018-2030)
Table 17: Diagnosed Cases of Psoriatic arthritis (PsA) in the United States (2018-2030)
Table 18: Age-specific Cases of Psoriatic Arthritis in the United States (2018-2030)
Table 19: Gender-specific cases of Psoriatic Arthritis in the United States (2018-2030)
Table 20: Severity-specific Prevalence of Psoriatic Arthritis in the United States (2018-2030)
Table 21: Prevalent Cases of Psoriatic arthritis (PsA) in Germany (2018-2030)
Table 22: Diagnosed Cases of Psoriatic arthritis (PsA) in Germany (2018-2030)
Table 23: Age-specific Cases of Psoriatic Arthritis in Germany (2018-2030)
Table 24: Gender-specific cases of Psoriatic Arthritis in Germany (2018-2030)
Table 25: Severity-specific Prevalence of Psoriatic Arthritis in Germany (2018-2030)
Table 26: Prevalent Cases of Psoriatic arthritis (PsA) in France (2018-2030)
Table 27: Diagnosed Cases of Psoriatic arthritis (PsA) in France (2018-2030)
Table 28: Age-specific Cases of Psoriatic Arthritis in France (2018-2030)
Table 29: Gender-specific cases of Psoriatic Arthritis in France (2018-2030)
Table 30: Severity-specific Prevalence of Psoriatic Arthritis in France (2018-2030)
Table 31: Prevalent Cases of Psoriatic arthritis (PsA) in Italy (2018-2030)
Table 32: Diagnosed Cases of Psoriatic arthritis (PsA) in Italy (2018-2030)
Table 33: Age-specific Cases of Psoriatic Arthritis in Italy (2018-2030)
Table 34: Gender-specific cases of Psoriatic Arthritis in Italy (2018-2030)
Table 35: Severity-specific Prevalence of Psoriatic Arthritis in Italy (2018-2030)
Table 36: Prevalent Cases of Psoriatic arthritis (PsA) in Spain (2018-2030)
Table 37: Diagnosed Cases of Psoriatic arthritis (PsA) in Spain (2018-2030)
Table 38: Age-specific Cases of Psoriatic Arthritis in Spain (2018-2030)
Table 39: Gender-specific cases of Psoriatic Arthritis in Spain (2018-2030)
Table 40: Severity-specific Prevalence of Psoriatic Arthritis in Spain (2018-2030)
Table 41: Prevalent Cases of Psoriatic arthritis (PsA) in the United Kingdom (2018-2030)
Table 42: Diagnosed Cases of Psoriatic arthritis (PsA) in the United Kingdom (2018-2030)
Table 43: Age-specific Cases of Psoriatic Arthritis in the United Kingdom (2018-2030)
Table 44: Gender-specific cases of Psoriatic Arthritis in the United Kingdom (2018-2030)
Table 45: Severity-specific Prevalence of Psoriatic Arthritis in the United Kingdom (2018-2030)
Table 46: Prevalent Cases of Psoriatic arthritis (PsA) in Japan (2018-2030)
Table 47: Diagnosed Cases of Psoriatic arthritis (PsA) in Japan (2018-2030)
Table 48: Age-specific Cases of Psoriatic Arthritis in the United States (2018-2030)
Table 49: Gender-specific cases of Psoriatic Arthritis in Japan (2018-2030)
Table 50: Severity-specific Prevalence of Psoriatic Arthritis in Japan (2018-2030)
Table 51: Organizations working actively in the field of PsA
Table 52: Key cross of the Marketed drugs
Table 53: Key cross of the Marketed drugs
Table 54: Skyrizi, Clinical Trial Description, 2021
Table 55: Rinvoq, Clinical Trial Description, 2021
Table 56: Deucravacitinib, Clinical Trial Description, 2021
Table 57: Tildrakizumab, Clinical Trial Description, 2021
Table 58: Bimekizumab, Clinical Trial Description, 2021
Table 59: Neihulizumab, Clinical Trial Description, 2021
Table 60: Brepocitinib, Clinical Trial Description, 2021
Table 61: Seven Major Market Size of Psoriatic arthritis (PsA) in USD Million (2018-2030)
Table 62: The US Market Size of Psoriatic arthritis (PsA) in USD Million (2018-2030)
Table 63:The US Market Size of Psoriatic Arthritis (PsA) by Systemic Therapies (Class-wise) in USD Million (2018-2030)
Table 64: The US Market Size of Psoriatic Arthritis (PsA) by Product in USD Million (2018-2030)
Table 65: The Germany Market Size of Psoriatic arthritis (PsA) in USD Million (2018-2030)
Table 66:The Germany Market Size of Psoriatic Arthritis (PsA) by Systemic Therapies (Class-wise) in USD Million (2018-2030)
Table 67: The Germany Market Size of Psoriatic Arthritis (PsA) by Product in USD Million (2018-2030)
Table 68: The France Market Size of Psoriatic arthritis (PsA) in USD Million (2018-2030)
Table 69:The France Market Size of Psoriatic Arthritis (PsA) by Systemic Therapies (Class-wise) in USD Million (2018-2030)
Table 70: The France Market Size of Psoriatic Arthritis (PsA) by Product in USD Million (2018-2030)
Table 71: The Italy Market Size of Psoriatic arthritis (PsA) in USD Million (2018-2030)
Table 72:The Italy Market Size of Psoriatic Arthritis (PsA) by Systemic Therapies (Class-wise) in USD Million (2018-2030)
Table 73: The Italy Market Size of Psoriatic Arthritis (PsA) by Product in USD Million (2018-2030)
Table 74: The Spain Market Size of Psoriatic arthritis (PsA) in USD Million (2018-2030)
Table 75:The Spain Market Size of Psoriatic Arthritis (PsA) by Systemic Therapies (Class-wise) in USD Million (2018-2030)
Table 76: The Spain Market Size of Psoriatic Arthritis (PsA) by Product in USD Million (2018-2030)
Table 77: The United Kingdom Market Size of Psoriatic arthritis (PsA) in USD Million (2018-2030)
Table 78:The United Kingdom Market Size of Psoriatic Arthritis (PsA) by Systemic Therapies (Class-wise) in USD Million (2018-2030)
Table 79: The United Kingdom Market Size of Psoriatic Arthritis (PsA) by Product in USD Million (2018-2030)
Table 80: The Japan Market Size of Psoriatic arthritis (PsA) in USD Million (2018-2030)
Table 81:The Japan Market Size of Psoriatic Arthritis (PsA) by Systemic Therapies (Class-wise) in USD Million (2018-2030)
Table 82: The Japan Market Size of Psoriatic Arthritis (PsA) by Product in USD Million (2018-2030)

List of Figures
Figure 1: Clinical Presentations
Figure 2: Classification of PsA
Figure 3: Risk Factors
Figure 4: Key cell types and secretion of key inflammatory mediators in psoriatic arthritis
Figure 5: Adaptive and innate immune cells and activated pathways in psoriatic arthritis
Figure 6: Diagnosis of PsA
Figure 7: Differential Diagnosis
Figure 8: Pharmacologic, non-pharmacologic, and symptomatic therapies for psoriatic arthritis
Figure 9: The EULAR 2019 algorithm for treatment of PsA with pharmacological non-topical treatments
Figure 10: Psoriatic Arthritis Treatment Pathway Following Inadequate Response to DMARDs (NICE)
Figure 11: Total Prevalent Population of Psoriatic arthritis (PsA) in 7MM (2018-2030)
Figure 12: Prevalent Cases of Psoriatic arthritis (PsA) in the United States (2018-2030)
Figure 13: Diagnosed Cases of Psoriatic arthritis (PsA) in the United States (2018-2030)
Figure 14: Age-specific Cases of Psoriatic Arthritis in the United States (2018-2030)
Figure 15: Gender-specific cases of Psoriatic Arthritis in the United States (2018-2030)
Figure 16: Severity-specific Prevalence of Psoriatic Arthritis in the United States (2018-2030)
Figure 17: Prevalent Cases of Psoriatic arthritis (PsA) in Germany (2018-2030)
Figure 18: Diagnosed Cases of Psoriatic arthritis (PsA) in Germany (2018-2030)
Figure 19: Age-specific Cases of Psoriatic Arthritis in Germany (2018-2030)
Figure 20: Gender-specific cases of Psoriatic Arthritis in Germany (2018-2030)
Figure 21: Severity-specific Prevalence of Psoriatic Arthritis in Germany (2018-2030)
Figure 22: Prevalent Cases of Psoriatic arthritis (PsA) in France (2018-2030)
Figure 23: Diagnosed Cases of Psoriatic arthritis (PsA) in France (2018-2030)
Figure 24: Age-specific Cases of Psoriatic Arthritis in France (2018-2030)
Figure 25: Gender-specific cases of Psoriatic Arthritis in France (2018-2030)
Figure 26: Severity-specific Prevalence of Psoriatic Arthritis in France (2018-2030)
Figure 27: Prevalent Cases of Psoriatic arthritis (PsA) in Italy (2018-2030)
Figure 28: Diagnosed Cases of Psoriatic arthritis (PsA) in Italy (2018-2030)
Figure 29: Age-specific Cases of Psoriatic Arthritis in Italy (2018-2030)
Figure 30: Gender-specific cases of Psoriatic Arthritis in Italy (2018-2030)
Figure 31: Severity-specific Prevalence of Psoriatic Arthritis in Italy (2018-2030)
Figure 32: Prevalent Cases of Psoriatic arthritis (PsA) in Spain (2018-2030)
Figure 33: Diagnosed Cases of Psoriatic arthritis (PsA) in Spain (2018-2030)
Figure 34: Age-specific Cases of Psoriatic Arthritis in Spain (2018-2030)
Figure 35: Gender-specific cases of Psoriatic Arthritis in Spain (2018-2030)
Figure 36: Severity-specific Prevalence of Psoriatic Arthritis in Spain (2018-2030)
Figure 37: Prevalent Cases of Psoriatic arthritis (PsA) in the United Kingdom (2018-2030)
Figure 38: Diagnosed Cases of Psoriatic arthritis (PsA) in the United Kingdom (2018-2030)
Figure 39: Age-specific Cases of Psoriatic Arthritis in the United Kingdom (2018-2030)
Figure 40: Gender-specific cases of Psoriatic Arthritis in the United Kingdom (2018-2030)
Figure 41: Severity-specific Prevalence of Psoriatic Arthritis in the United Kingdom (2018-2030)
Figure 42: Prevalent Cases of Psoriatic arthritis (PsA) in Japan (2018-2030)
Figure 43: Diagnosed Cases of Psoriatic arthritis (PsA) in Japan (2018-2030)
Figure 44: Age-specific Cases of Psoriatic Arthritis in Japan (2018-2030)
Figure 45: Gender-specific cases of Psoriatic Arthritis Japan (2018-2030)
Figure 46: Severity-specific Prevalence of Psoriatic Arthritis in Japan (2018-2030)
Figure 47: Seven Major Market Size of Psoriatic arthritis (PsA) in USD Million (2018-2030)
Figure 48: The US Market Size of Psoriatic arthritis (PsA) in USD Million (2018-2030)
Figure 49: The US Market Size of Psoriatic Arthritis (PsA) by Systemic Therapies (Class-wise) (2018-2030)
Figure 50: The US Market Size of Psoriatic Arthritis (PsA) by Product in USD Million (2018-2030)
Figure 51: The Germany Market Size of Psoriatic arthritis (PsA) in USD Million (2018-2030)
Figure 52: The Germany Market Size of Psoriatic Arthritis (PsA) by Systemic Therapies (Class-wise) (2018-2030)
Figure 53: The Germany Market Size of Psoriatic Arthritis (PsA) by Product in USD Million (2018-2030)
Figure 54: The France Market Size of Psoriatic arthritis (PsA) in USD Million (2018-2030)
Figure 55: The France Market Size of Psoriatic Arthritis (PsA) by Systemic Therapies (Class-wise) (2018-2030)
Figure 56: The France Market Size of Psoriatic Arthritis (PsA) by Product in USD Million (2018-2030)
Figure 57: The Italy Market Size of Psoriatic arthritis (PsA) in USD Million (2018-2030)
Figure 58: The Italy Market Size of Psoriatic Arthritis (PsA) by Systemic Therapies (Class-wise) (2018-2030)
Figure 59: The Italy Market Size of Psoriatic Arthritis (PsA) by Product in USD Million (2018-2030)
Figure 60: The Spain Market Size of Psoriatic arthritis (PsA) in USD Million (2018-2030)
Figure 61: The Spain Market Size of Psoriatic Arthritis (PsA) by Systemic Therapies (Class-wise) (2018-2030)
Figure 62: The Spain Market Size of Psoriatic Arthritis (PsA) by Product in USD Million (2018-2030)
Figure 63: The United Kingdom Market Size of Psoriatic arthritis (PsA) in USD Million (2018-2030)
Figure 64: The United Kindom Market Size of Psoriatic Arthritis (PsA) by Systemic Therapies (Class-wise) (2018-2030)
Figure 65: The United Kingdom Market Size of Psoriatic Arthritis (PsA) by Product in USD Million (2018-2030)
Figure 66: The Japan Market Size of Psoriatic arthritis (PsA) in USD Million (2018-2030)
Figure 67: The Japan Market Size of Psoriatic Arthritis (PsA) by Systemic Therapies (Class-wise) (2018-2030)
Figure 68: The Japan Market Size of Psoriatic Arthritis (PsA) by Product in USD Million (2018-2030)
Note: Product cover images may vary from those shown
  • AbbVie
  • Amgen/Pfizer
  • Bristol-Myers Squibb
  • Janssen Biotech
  • Janssen Biotech
  • Amgen
  • Janssen Biotech
  • Eli Lilly and Company
  • Novartis
  • Janssen Biotech
  • Pfizer
  • UCB
  • AbbVie
  • AbbVie
  • Bristol-Myers Squibb
  • Sun Pharma Global FZE
  • UCB Biopharma
  • AltruBio
  • Pfizer
Note: Product cover images may vary from those shown
Adroll
adroll